1.Maruvada, P, Leone, V, Kaplan, LM et al. (2017) The human microbiome and obesity: moving beyond associations. Cell Host Microbe 22, 589–599.
2.Perumpail, BJ, Khan, MA, Yoo, ER et al. (2017) Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol 23, 8263–8276.
3.Torres-Fuentes, C, Schellekens, H, Dinan, TG et al. (2017) The microbiota-gut-brain axis in obesity. Lancet Gastroenterol Hepatol 2, 747–756.
4.Cotillard, A, Kennedy, SP, Kong, LC et al. (2013) Dietary intervention impact on gut microbial gene richness. Nature 500, 585–588.
5.Cani, PD, Bibiloni, R, Knauf, C et al. (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470–1481.
6.Brandl, K, Kumar, V & Eckmann, L (2017) Gut-liver axis at the frontier of host-microbial interactions. Am J Physiol Gastrointest Liver Physiol 312, G413-g419.
7.Husted, AS, Trauelsen, M, Rudenko, O et al. (2017) GPCR-mediated signaling of metabolites. Cell Metab 25, 777–796.
8.Hubbard, TD, Murray, IA & Perdew, GH (2015) Indole and tryptophan metabolism: endogenous and dietary routes to Ah Receptor Activation. Drug Metab Dispos 43, 1522–1535.
9.Krishnan, S, Ding, Y, Saedi, N et al. (2018) Gut microbiota-derived tryptophan metabolites modulate inflammatory response in hepatocytes and macrophages. Cell Rep 23, 1099–1111.
10.Cani, PD, Osto, M, Geurts, L et al. (2012) Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 3, 279–288.
11.Cani, PD, Amar, J, Iglesias, MA et al. (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761–1772.
12.Cani, PD, Possemiers, S, Van de Wiele, T et al. (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58, 1091–1103.
13.Neyrinck, AM, Van Hee, VF, Piront, N et al. (2012) Wheat-derived arabinoxylan oligosaccharides with prebiotic effect increase satietogenic gut peptides and reduce metabolic endotoxemia in diet-induced obese mice. Nutr Diabetes 2, e28.
14.Al-Attas, OS, Al-Daghri, NM, Al-Rubeaan, K et al. (2009) Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc Diabetol 8, 20.
15.Galic, S, Oakhill, JS & Steinberg, GR (2010) Adipose tissue as an endocrine organ. Mol Cell Endocrinol 316, 129–139.
16. Tilg, H & Moschen, AR (2014) Microbiota and diabetes: an evolving relationship. Gut 63, 1513–1521.
17.Le Chatelier, E, Nielsen, T, Qin, J et al. (2013) Richness of human gut microbiome correlates with metabolic markers. Nature 500, 541.
18.Furet, JP, Kong, LC, Tap, J et al. (2010) Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 59, 3049–3057.
19.Castaner, O, Goday, A, Park, Y-M et al. (2018) The gut microbiome profile in obesity: a systematic review. Int J Endocrinol 2018, 9.
20.Everard, A, Belzer, C, Geurts, L et al. (2013) Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 110, 9066–9071.
21.Plovier, H, Everard, A, Druart, C et al. (2017) A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med 23, 107–113.
22.Haas, JT, Francque, S & Staels, B (2016) Pathophysiology and mechanisms of nonalcoholic fatty liver disease. In Annual Review of Physiology, vol 78, pp. 181–205. [Julius, D, editor]. Palo Alto: Annual Reviews.
23.Tilg, H, Cani, PD & Mayer, EA (2016) Gut microbiome and liver diseases. Gut 65, 2035–2044.
24.Abdou, RM, Zhu, L, Baker, RD et al. (2016) Gut microbiota of nonalcoholic fatty liver disease. Dig Dis Sci 61, 1268–1281.
25.Duarte, SMB, Stefano, JT, Miele, L et al. (2018) Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study. Nutr Metab Cardiovasc Dis 28, 369–384.
26.Le Roy, T, Llopis, M, Lepage, P et al. (2013) Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62, 1787–1794.
27.Miele, L, Valenza, V, La Torre, G et al. (2009) Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49, 1877–1887.
28.Henao-Mejia, J, Elinav, E, Jin, C et al. (2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179.
29.Bashiardes, S, Shapiro, H, Rozin, S et al. (2016) Non-alcoholic fatty liver and the gut microbiota. Mol Metab 5, 782–794.
30.Da Silva, HE, Teterina, A, Comelli, EM et al. (2018) Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep 8, 1466.
31.Jiang, W, Wu, N, Wang, X et al. (2015) Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep 5, 8096.
32.Wong, VW, Tse, CH, Lam, TT et al. (2013) Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis – a longitudinal study. PLoS One 8, e62885.
33.Zhu, L, Baker, SS, Gill, C et al. (2013) Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57, 601–609.
34.Boursier, J, Mueller, O, Barret, M et al. (2016) The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63, 764–775.
35.Hoyles, L, Fernandez-Real, JM, Federici, M et al. (2018) Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med 24, 1070–1080.
36.Shen, F, Zheng, RD, Sun, XQ et al. (2017) Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 16, 375–381.
37.Michail, S, Lin, M, Frey, MR et al. (2015) Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol 91, 1–9.
38.Raman, M, Ahmed, I, Gillevet, PM et al. (2013) Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 11, 868–875. e861–e863.
39.Postler, TS & Ghosh, S (2017) Understanding the holobiont: how microbial metabolites affect human health and shape the immune system. Cell Metab 26, 110–130.
40.Ridlon, JM, Kang, DJ & Hylemon, PB (2006) Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47, 241–259.
41.Leung, C, Rivera, L, Furness, JB et al. (2016) The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol 13, 412–425.
42. Nyangale, EP, Mottram, DS & Gibson, GR (2012) Gut microbial activity, implications for health and disease: the potential role of metabolite analysis. J Proteome Res 11, 5573–5585.
43.Boets, E, Deroover, L, Houben, E et al. (2015) Quantification of in vivo colonic short chain fatty acid production from inulin. Nutrients 7, 8916–8929.
44.Wong, JM, de Souza, R, Kendall, CW et al. (2006) Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 40, 235–243.
45.Nicholson, JK, Holmes, E, Kinross, J et al. (2012) Host-gut microbiota metabolic interactions. Science 336, 1262–1267.
46.Wright, RS, Anderson, JW & Bridges, SR (1990) Propionate inhibits hepatocyte lipid synthesis. Proc Soc Exp Biol Med 195, 26–29.
47.Demigne, C, Morand, C, Levrat, MA et al. (1995) Effect of propionate on fatty acid and cholesterol synthesis and on acetate metabolism in isolated rat hepatocytes. Br J Nutr 74, 209–219.
48.Svegliati-Baroni, G, Saccomanno, S, Rychlicki, C et al. (2011) Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 31, 1285–1297.
49.Bindels, LB, Dewulf, EM & Delzenne, NM (2013) GPR43/FFA2: physiopathological relevance and therapeutic prospects. Trends Pharmacol Sci 34, 226–232.
50.Bjursell, M, Admyre, T, Goransson, M et al. (2011) Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am J Physiol Endocrinol Metab 300, E211–E220.
51.Kimura, I, Ozawa, K, Inoue, D et al. (2013) The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun 4, 1829.
52.Sun, B, Jia, Y, Hong, J et al. (2018) Sodium butyrate ameliorates high-fat-diet-induced non-alcoholic fatty liver disease through peroxisome proliferator-activated receptor alpha-mediated activation of beta oxidation and suppression of inflammation. J Agric Food Chem 66, 7633–7642.
53.Fu, ZD & Cui, JY (2017) Remote sensing between liver and intestine: importance of microbial metabolites. Curr Pharmacol Rep 3, 101–113.
54.Chavez-Talavera, O, Tailleux, A, Lefebvre, P et al. (2017) Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 152, 1679–1694. e1673.
55.Legry, V, Francque, S, Haas, JT et al. (2017) Bile acid alterations are associated with insulin resistance, but not with NASH, in obese subjects. J Clin Endocrinol Metab 102, 3783–3794.
56.Wikoff, WR, Anfora, AT, Liu, J et al. (2009) Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A 106, 3698–3703.
57.Zheng, X, Xie, G, Zhao, A et al. (2011) The footprints of gut microbial-mammalian co-metabolism. J Proteome Res 10, 5512–5522.
58.Agus, A, Planchais, J & Sokol, H (2018) Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 23, 716–724.
59.Roager, HM & Licht, TR (2018) Microbial tryptophan catabolites in health and disease. Nat Commun 9, 3294.
60.Jin, UH, Lee, SO, Sridharan, G et al. (2014) Microbiome-derived tryptophan metabolites and their aryl hydrocarbon receptor-dependent agonist and antagonist activities. Mol Pharmacol 85, 777–788.
61.Chimerel, C, Emery, E, Summers, DK et al. (2014) Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep 9, 1202–1208.
62.Banoglu, E, Jha, GG & King, RS (2001) Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate. Eur J Drug Metab Pharmacokinet 26, 235–240.
63.Banoglu, E & King, RS (2002) Sulfation of indoxyl by human and rat aryl (phenol) sulfotransferases to form indoxyl sulfate. Eur J Drug Metab Pharmacokinet 27, 135–140.
64.Beaumont, M, Neyrinck, AM, Olivares, M et al. (2018) The gut microbiota metabolite indole alleviates liver inflammation in mice. FASEB J 32, 6681–6693.
65.Natividad, JM, Agus, A, Planchais, J et al. (2018) Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome. Cell Metab 28, 737–749.
66.Russell, WR, Duncan, SH, Scobbie, L et al. (2013) Major phenylpropanoid-derived metabolites in the human gut can arise from microbial fermentation of protein. Mol Nutr Food Res 57, 523–535.
67.Windey, K, De Preter, V & Verbeke, K (2012) Relevance of protein fermentation to gut health. Mol Nutr Food Res 56, 184–196.
68.Andriamihaja, M, Lan, A, Beaumont, M et al. (2015) The deleterious metabolic and genotoxic effects of the bacterial metabolite p-cresol on colonic epithelial cells. Free Radic Biol Med 85, 219–227.
69.Beaumont, M, Portune, KJ, Steuer, N et al. (2017) Quantity and source of dietary protein influence metabolite production by gut microbiota and rectal mucosa gene expression: a randomized, parallel, double-blind trial in overweight humans. Am J Clin Nutr 106, 1005–1019.
70.Russell, WR, Gratz, SW, Duncan, SH et al. (2011) High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health. Am J Clin Nutr 93, 1062–1072.
71.Hill, C, Guarner, F, Reid, G et al. (2014) Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11, 506–514.
72.Gibson, GR, Hutkins, R, Sanders, ME et al. (2017) Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 14, 491–502.
73. Gibson, GR & Roberfroid, MB (1995) Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 125, 1401–1412.
74.Loman, BR, Hernandez-Saavedra, D, An, R et al. (2018) Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Nutr Rev 76, 822–839.
75.S Lavekar, A, V Raje, D, Manohar, T et al. (2017) Role of probiotics in the treatment of nonalcoholic fatty liver disease: a meta-analysis. Euroasian J Hepatogastroenterol 7, 130–137.
76.Aller, R, De Luis, DA, Izaola, O et al. (2011) Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 15, 1090–1095.
77.Wong, VW, Won, GL, Chim, AM et al. (2013) Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol 12, 256–262.
78.Alisi, A, Bedogni, G, Baviera, G et al. (2014) Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 39, 1276–1285.
79.Bindels, LB, Delzenne, NM, Cani, PD et al. (2015) Towards a more comprehensive concept for prebiotics. Nat Rev Gastroenterol Hepatol 12, 303–310.
80.Roberfroid, M, Gibson, GR, Hoyles, L et al. (2010) Prebiotic effects: metabolic and health benefits. Br J Nutr 104 Suppl 2, S1–63.
81.Delzenne, NM, Cani, PD, Everard, A et al. (2015) Gut microorganisms as promising targets for the management of type 2 diabetes. Diabetologia 58, 2206–2217.
82.Catry, E, Bindels, LB, Tailleux, A et al. (2018) Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction. Gut 67, 271–283.
83.Mokhtari, Z, Gibson, DL & Hekmatdoost, A (2017) Nonalcoholic fatty liver disease, the gut microbiome, and diet. Adv Nutr 8, 240–252.
84.Parnell, JA, Raman, M, Rioux, KP et al. (2012) The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int 32, 701–711.
85.Dewulf, EM, Cani, PD, Claus, SP et al. (2013) Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 62, 1112–1121.
86.Daubioul, CA, Horsmans, Y, Lambert, P et al. (2005) Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr 59, 723–726.
87. Kellow, NJ, Coughlan, MT & Reid, CM (2014) Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials. Br J Nutr 111, 1147–1161.
88.Parnell, JA, Klancic, T & Reimer, RA (2017) Oligofructose decreases serum lipopolysaccharide and plasminogen activator inhibitor-1 in adults with overweight/obesity. Obesity (Silver Spring) 25, 510–513.
89.Letexier, D, Diraison, F & Beylot, M (2003) Addition of inulin to a moderately high-carbohydrate diet reduces hepatic lipogenesis and plasma triacylglycerol concentrations in humans. Am J Clin Nutr 77, 559–564.
90.Lambert, JE, Parnell, JA, Eksteen, B et al. (2015) Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterol 15, 169.
91.Bakhshimoghaddam, F, Shateri, K, Sina, M et al. (2018) Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. J Nutr 148, 1276–1284.
92.Malaguarnera, M, Vacante, M, Antic, T et al. (2012) Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 57, 545–553.
93.Ferolla, SM, Couto, CA, Costa-Silva, L et al. (2016) Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters, but not on gut permeability in a population with nonalcoholic steatohepatitis. Nutrients 8, 397.
94.Scorletti, E, Afolabi, PR, Miles, EA et al. (2018) Design and rationale of the INSYTE study: a randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease. Contemp Clin Trials 71, 113–123.
95.Vrieze, A, Van Nood, E, Holleman, F et al. (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143, 913–916. e917.
96.Kootte, RS, Levin, E, Salojarvi, J et al. (2017) Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab 26, 611–619.